BiologybioRxiv
Heuristic editor, no API keyVerdict: NotableA minimally modified AAV9 variant (AAV9fyhr) for enhanced CNS gene delivery by intra-CSF administration
Adeno-associated virus (AAV) mediated gene therapies continue to show promise for the treatment of genetic diseases.
Key numbers
- 6-fold higher gene delivery across
Caveats
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
Adeno-associated virus (AAV) mediated gene therapies continue to show promise for the treatment of genetic diseases. However, delivery and safety still represent significant prohibitive barriers restricting translation of these delivery modalities to humans. We describe a novel AAV9 variant, AAV9fyhr or FYHR, identified from screening a controlled randomization point mutation AAV9 library in mice and nonhuman primates followed by directed evolution of in vivo CNS-derived libraries screened in human iPSC differentiated cortical neurons. Capsid variants of interest were identified by coupling long read sequencing and computational structure modeling. Structure-function analysis of our lead candidate reveal that two targeted amino acid changes are sufficient to result in beneficial pleiotropic effects across viral stability, cell surface attachment, and gene delivery. We developed a novel multiplexed barcoding reporter system, enabling a time and cost-effective option to gather spatially resolved single cell capsid validation data in mice and nonhuman primates. When administered intrathecally, AAV9fyhr exhibits 2-to-6-fold higher gene delivery across several tissues in the CNS while minimally altering the tropism to peripheral tissues in comparison to AAV9. These findings demonstrate the potential of whole capsid engineering for the rational development of translational next generation AAV capsids.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ███░░ 3 | 24% | A method or resource many groups across the field will adopt within a year. |
| Magnitude | ███░░ 3 | 16% | Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 20% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 10% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we report); gains (x-fold); design (randomized); verification (experimental validation); stakes (genetic disease, prevention or cure). Red flags: derivative (modified version).
How the score was computed
- Merit
- 5.4 / 10
- Adjusted merit
- 4.6 / 10
- Attention
- 0%
- Freshness
- 88%